EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Harvard Apparatus Regenerative Technology EBITDA Margin % Related Terms
Harvard Apparatus Regenerative Technology EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HRGN vs DTEAF, WYGC, BFNH: EBITDA Margin % Comparison
For the Packaged Foods subindustry, Harvard Apparatus Regenerative Technology's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harvard Apparatus Regenerative Technology EBITDA Margin % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Harvard Apparatus Regenerative Technology's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Harvard Apparatus Regenerative Technology's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harvard Apparatus Regenerative Technology (HRGN) has a EBITDA Margin % of -695.13% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Harvard Apparatus Regenerative Technology and its competitors. According to the industry distribution chart, Harvard Apparatus Regenerative Technology ranks #1931 out of 1953 companies in the Consumer Packaged Goods industry, placing it in the top 98.9%.
Is Harvard Apparatus Regenerative Technology's EBITDA Margin % too high?
Harvard Apparatus Regenerative Technology's current EBITDA Margin % is -695.13%. Based on the distribution chart, Harvard Apparatus Regenerative Technology ranks #1931 out of 1953 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Harvard Apparatus Regenerative Technology has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Harvard Apparatus Regenerative Technology's EBITDA Margin % compare to DTEAF and WYGC?
According to the Consumer Packaged Goods industry distribution chart, Harvard Apparatus Regenerative Technology ranks #1931 out of 1953 companies for EBITDA Margin %. This places Harvard Apparatus Regenerative Technology in the lower half of its industry. The industry median EBITDA Margin % is 8.99. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Consumer Packaged Goods company?
The median EBITDA Margin % among Consumer Packaged Goods companies is 8.99, based on 1,953 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Harvard Apparatus Regenerative Technology and its competitors. For the Consumer Packaged Goods industry, the median EBITDA Margin % is 8.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harvard Apparatus Regenerative Technology's current EBITDA Margin % is -695.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Apparatus Regenerative Technology stock overvalued right now?
Based on GuruFocus' analysis, Harvard Apparatus Regenerative Technology (HRGN) is currently considered Possible Value Trap. The stock's GF Value™ is $5.34, compared to a current price of $1.39 — trading 74% below its estimated fair value. The current EBITDA Margin % is -695.13%. Harvard Apparatus Regenerative Technology's overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Harvard Apparatus Regenerative Technology (HRGN), the current EBITDA Margin % is -695.13% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harvard Apparatus Regenerative Technology (HRGN) Overvalued in 2026?
Based on GuruFocus' analysis, Harvard Apparatus Regenerative Technology stock appears to be undervalued.
The current stock price of $1.39 is trading 74% below its estimated GF Value™ of $5.34.
GuruFocus considers Harvard Apparatus Regenerative Technology to be Possible Value Trap.
Key valuation signals for HRGN:
EBITDA Margin %: -695.13%
GF Value™: $5.34 vs. price of $1.39 (74% below fair value)
No single metric tells the full story. See the HRGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harvard Apparatus Regenerative Technology Business Description
Harvard Apparatus Regenerative Technology is a clinical-stage biotechnology company focused on the development of regenerative medicine treatments for disorders of the gastrointestinal system and other organs that result from cancer, trauma, or birth defects. Its technology is based on a proprietary cell-therapy platform that uses a patient's own stem cells to regenerate and restore function to damaged organs. The Company has two operating and reportable segments: Regenerative Biotech, focused on the development of regenerative medicine treatments with operations currently in the United States, and Consumer Health Products relating to consumer health products with operations currently in Asia.
34GF Score
Get the complete analysis for HRGN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HRGN has been successfully added to your 
